Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

• Main Authors: Katjana S. Schwab, Glenn Kristiansen, Hans H. Schild, Stefanie E.A. Held, Annkristin Heine, Peter Brossart
• Format: Article
• Language: English
• Published: Karger Publishers 2018-01-01
• Series: Case Reports in Oncology
• Subjects: Nivolumab; Ipilimumab; Squamous cell carcinoma; Anti-PD-1 inhibitor; Anti-CTLA4 antibody; Anti-programmed cell death protein 1 inhibitor
• Online Access: https://www.karger.com/Article/FullText/485562

Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HNSCC who have disease progression on or after platinum-based therapy. Recently, in patients with metastatic malignant melanoma a significant improvement of outcome and response was achieved with the combination of ipilimumab (CTLA4 antibody) and the programmed death (PD)-1 inhibitor nivolumab compared with monotherapy. Based on these results, the combination of nivolumab and ipilimumab has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma. So far, there have been no data concerning the combination of nivolumab and ipilimumab in squamous cell head and neck cancer. We here present the case of a 46-year-old male with refractory squamous cell head and neck cancer, who was successfully treated with the PD-1 inhibitor nivolumab in combination with the anti-CTLA4 antibody ipilimumab.